SPNS3 and acute myeloid leukemia: Primarily, we planned to definite whether SPNS3 could serves as a biomarker that indicates the prognosis of AML at the first diagnosis and build the correlation of the AML cells’ phenotype with the clinical significance of SPNS3 through experiments.